- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Fr | ASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME | - | HKEx | ||
| 18.06. | HSI Down 269 pts; HSTI Down 77 pts; MEITUAN Down over 3%; CHINAHONGQIAO, UNITEDENERGY GP, ASCENTAGE, OCUMENSION-B, SHANGHAI IND H Hit New Highs; Market Turnover Rises | 4 | AASTOCKS | ||
| 18.06. | HSI Down 281 pts; HSTI Down 83 pts; MEITUAN Down over 3%; UNITEDENERGY GP, ASCENTAGE, FORTUNE REIT, GUANGDONG INV Hit New Highs | 4 | AASTOCKS | ||
| 16.06. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST RESULTS FROM MULTIPLE CLINICAL STUDIES IN 2025 EUROPEAN HEMATOLOGY ASSOCIATION ... | - | HKEx | ||
| 16.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL | 144 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| ASCENTAGE PHARMA GROUP INTERNATIONAL ADR Aktie jetzt für 0€ handeln | |||||
| 11.06. | CICC Lifts ASCENTAGE-B's TP to HKD69 on Impressive APG-2575 Data | 2 | AASTOCKS | ||
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress | 1 | GlobeNewswire (USA) | ||
| 03.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors | 67 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| 03.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report | 1 | GlobeNewswire (USA) | ||
| 23.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 | 57 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| 23.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING AN ORAL ... | 2 | HKEx | ||
| 20.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.05. | ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 19, 2025 | - | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SECOND PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2025 | - | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SUPPLEMENTAL CIRCULAR - (1) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; (2) PROPOSED AMENDMENTS TO THE 2022 RSU SCHEME; (3) PROPOSED ... | - | HKEx | ||
| 29.04. | AACR 2025: Quintet of investigational oncological drugs puts Ascentage on positive ascent | - | pharmaphorum |
1 2 3 4 5 Weiter >>
85 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | 0,00 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | 0,00 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | 0,00 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | 0,00 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | 0,00 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
| NUVALENT | 79,66 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 18,215 | 0,00 % | ARS Pharmaceuticals, Inc. - 8-K, Current Report | ||
| VERVE THERAPEUTICS | 11,310 | 0,00 % | BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside |
ASCENTAGE PHARMA GROUP INTERNATIONAL ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 32,200 Euro und damit -1,83 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL ADR finden Sie auf Wallstreet Online.